StreetInsider.com News Articles

Gossamer Bio plans NDA submission for seralutinib in September 2026

Mon, 27 Jul 2026 07:02:27 -0400

Gossamer Bio, Inc. (Nasdaq: GOSS) announced it plans to submit a New Drug Application (NDA) for seralutinib, a treatment for pulmonary arterial hypertension (PAH), in September 2026, following a Pre-NDA Type B meeting with the U.S. Food and Drug Administration (FDA) and receipt of official meeting minutes.

The FDA characterized the degree of statistical significance and the magnitude of the treatment effect observed in the Phase 3 PROSERA trial as review issues rather than filing issues. On that basis, Gossamer intends to support the NDA with data from the PROSERA study, the Phase 2 TORREY study, and supportive analyses. If the

Gossamer Bio plans NDA submission for seralutinib in September 2026

Mon, 27 Jul 2026 07:02:27 -0400

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Mon, 27 Jul 2026 07:00:00 -0400

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –

– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity –

– Stockholders Approved Proposals Related to Convertible Note Exchange and Reverse Stock Split, Supporting a Strengthened Capital Structure –

– Cash, Cash Equivalents and Marketable Securities Totaled Approximately $57 Million as of June 30, 2026 –

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of

Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.

Fri, 24 Jul 2026 21:15:00 -0400

si-local-file:///var/storage/secattach/20260724/26814567.html

Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.

Fri, 24 Jul 2026 21:15:00 -0400

si-local-file:///var/storage/secattach/20260724/26814567.html

Form 8-K Gossamer Bio, Inc. For: Jul 14

Wed, 15 Jul 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260715/26770307.html

Form 8-K Gossamer Bio, Inc. For: Jul 14

Wed, 15 Jul 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260715/26770307.html

Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.

Wed, 01 Jul 2026 21:24:00 -0400

si-local-file:///var/storage/secattach/20260701/26722782.html

Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: D. E. SHAW & CO, L.P.

Wed, 01 Jul 2026 21:24:00 -0400

si-local-file:///var/storage/secattach/20260701/26722782.html

Gossamer Bio sets conversion rate for 2030 convertible notes

Wed, 01 Jul 2026 09:03:04 -0400

Gossamer Bio, Inc. (NASDAQ: GOSS) has announced the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030, set at 5,347.5936 shares of common stock per $1,000 principal amount, representing a conversion price of approximately $0.19 per share.

The initial exercise price for the company's accompanying Purchase Warrants was set at $0.34 per whole share of common stock.

Both figures were determined using a "Reference Price" of $0.17, calculated over a seven trading-day period beginning June 22, 2026, in accordance with the terms of the notes and warrants.

The conversion rate was calculated as the lesser of 5,347.5936 or

Gossamer Bio sets conversion rate for 2030 convertible notes

Wed, 01 Jul 2026 09:03:04 -0400

The initial exercise price for the company's accompanying Purchase Warrants was set at $0.34 per whole share of common stock.

Both figures were determined using a "Reference Price" of $0.17, calculated over a seven trading-day period beginning June 22, 2026, in accordance with the terms of the notes and warrants.

The conversion rate was calculated as the lesser of 5,347.5936 or

Form 8-K Gossamer Bio, Inc. For: Jul 01

Wed, 01 Jul 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260701/26717823.html

Form 8-K Gossamer Bio, Inc. For: Jul 01

Wed, 01 Jul 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260701/26717823.html

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

Wed, 01 Jul 2026 09:00:00 -0400

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 (the “2030 Convertible Notes”) will be 5,347.5936 shares of the Company’s common stock per $1,000 principal amount of the 2030 Convertible Notes, which represents a conversion price of approximately $0.19 per share of common stock, and the initial

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

Wed, 01 Jul 2026 09:00:00 -0400

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

Wed, 01 Jul 2026 09:00:00 -0400

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

Wed, 01 Jul 2026 09:00:00 -0400

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio Inc. (GOSS) PT Lowered to $2 at H.C. Wainwright

Fri, 26 Jun 2026 06:41:13 -0400

(Updated - June 26, 2026 6:41 AM EDT)

H.C. Wainwright analyst Patrick Trucchio lowered the price target on Gossamer Bio Inc. (NASDAQ: GOSS) to $2.00 (from $5.00) while maintaining a Buy rating.

The analyst commented: "On June 15-16, we hosted Gossamer management for a VNDR with buy-side investors, with participation from CFO and COO Bryan Giraudo, CCO Bob Smith, and VP of Corporate Finance and Communications Evan Belcher. Across the VNDR discussions, management reiterated that it expects to receive the minutes from its June Type B in-person meeting with the FDA in mid-July, followed by a discussion of the FDA's feedback on